CABALETTA BIO, INC.

CABA ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-167.9M $-115.9M $-67.7M $-53.0M $-46.3M $-33.3M $-16.9M $-12.2M
Depreciation & Amortization
Depreciation $1.6M $1.7M $1.4M $1.2M $733.0K $354.0K $104.0K $0
Amortization
Stock-Based Compensation $20.9M $19.5M $11.3M $6.9M $5.8M $4.4M $2.3M $606.0K
Net Cash from Operating Activities $-131.1M $-88.2M $-53.5M $-46.4M $-34.1M $-26.8M $-16.0M $-4.7M
Investing Activities
Capital Expenditures $1.2M $2.2M $687.0K $2.5M $1.2M $635.0K $693.0K
Business Acquisitions
Net Cash from Investing Activities $-50.3M $47.3M $-22.5M $-27.2M $6.0M $-8.0M $-693.0K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $100.3M $11.7M $187.6M $33.0M $48.9M $-24.0K $119.9M $37.7M
Net Change in Cash $-81.0M $-29.3M $111.6M
Free Cash Flow $-132.3M $-90.4M $-54.2M $-48.8M $-35.3M $-27.4M $-16.7M